- Certain Birth Control Pills, Devices Linked to Higher Heart Risks
- Ready for a Romantic Relationship? Your Friends’ Opinions Matter
- More Sunshine in Pregnancy, Infancy Could Benefit Kids With MS
- Enjoying Valentine’s Day When a Loved One Has Alzheimer’s
- Could Yogurt Lower Your Odds for Deadly Colon Cancers?
- Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
- Canned Tuna Recalled in Dozens of States Over Risk of Food Poisoning
- More Evidence Ozempic Can Curb Alcoholism
- In People With Autism, ADHD Rates Still Common in Adulthood
- Almost Half of Rural Americans Face Long Drives for Surgery
Natpara Approved for Hormone Disorder Causing Low Blood Calcium

Natpara (parathyroid hormone) has been approved by the U.S. Food and Drug Administration to control low blood calcium among people with hypoparathyroidism.
Hypoparathyroidism is a rare disease that occurs when the body doesn’t secrete enough parathyroid hormone, which regulates blood levels of calcium and phosphorus.
Hypoparathyroidism is typically caused by malfunctioning or surgically removed parathyroid glands. The condition affects about 60,000 people in the United States, the FDA said in a news release. Symptoms commonly include numbness, tingling, muscle twitching, cramps, abnormal heart rhythm and seizures. Longer-term complications may include kidney damage, kidney stones and cataracts.
Natpara, a once-daily injection, was evaluated in a clinical study of 124 people. Forty-two percent of those treated with Natpara achieved normal blood calcium levels, the FDA said.
The drug’s label includes a boxed warning that bone cancer had been observed in a study of rats given Natpara. However, it’s unknown if the drug would cause bone cancer among people, the FDA said.
The most common side effects of Natpara include tingling, pricking and burning of the skin, low blood calcium, headache, high blood calcium and nausea.
Natpara is produced by NPS Pharmaceuticals, based in Bedminster, N.J.
More information
Learn more by visiting the FDA.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.